RNA Readouts And Clinical Milestones Will Broaden Treatment Horizons

Shared on01 May 25
Fair value Increased 52%

Shared on24 Apr 25
Fair value Decreased 38%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.3%.

Shared on17 Apr 25
Fair value Increased 5.32%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 9.20%

Shared on02 Apr 25
Fair value Decreased 2.01%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.